Corline Biomedical Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Henrik Nittmar
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 17.2yrs |
| CEO ownership | 2.5% |
| Management average tenure | no data |
| Board average tenure | 8.2yrs |
Recent management updates
Recent updates
Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business
Aug 24
We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth
Mar 15We're Interested To See How Corline Biomedical (STO:CLBIO) Uses Its Cash Hoard To Grow
Nov 26Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business
Jun 22We Think Corline Biomedical (STO:CLBIO) Can Easily Afford To Drive Business Growth
Feb 16Companies Like Corline Biomedical (STO:CLBIO) Are In A Position To Invest In Growth
Jun 14Here's Why We're Watching Corline Biomedical's (STO:CLBIO) Cash Burn Situation
Feb 28CEO
Henrik Nittmar (58 yo)
17.2yrs
Tenure
Dr. Henrik Nittmar, Ph. D., has been the Chief Executive Officer of Corline Biomedical AB (publ) (alternate name Corline Systems AB) since 2008. Dr. Nittmar works as an Investment Manager for a select numb...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Non-Executive Director | 3.2yrs | no data | no data | |
| Non-Executive Director | 20.2yrs | no data | 8.62% SEK 20.0m | |
| Independent Non-Executive Director | 8.2yrs | SEK 105.00k | no data | |
| Chairman | 20.2yrs | no data | 24.78% SEK 57.5m | |
| Independent Non-Executive Director | 7.8yrs | SEK 105.00k | no data | |
| Scientific Advisor | 8.2yrs | no data | no data | |
| Independent Non-Executive Director | 5.2yrs | no data | no data |
8.2yrs
Average Tenure
53.5yo
Average Age
Experienced Board: CLBIO's board of directors are considered experienced (8.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/17 09:46 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Corline Biomedical AB is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ludvig Svensson | Penser Access |
| Gustaf Meyer | Redeye |